SPDR S&P Biotech ETF
774 hedge funds and large institutions have $9.74B invested in SPDR S&P Biotech ETF in 2024 Q1 according to their latest regulatory filings, with 128 funds opening new positions, 255 increasing their positions, 233 reducing their positions, and 81 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
774
Holders Change
+36
Holders Change %
+4.88%
% of All Funds
11.22%
Holding in Top 10
23
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.33%
New
128
Increased
255
Reduced
233
Closed
81
Calls
$2.25B
Puts
$3.97B
Net Calls
-$1.72B
Net Calls Change
-$470M
Top Buyers
| 1 |
Citigroup
New York
|
+$447M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$391M |
| 3 |
JPMorgan Chase & Co
New York
|
+$356M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$280M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$131M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$326M |
| 2 |
MCM
Moore Capital Management
New York
|
-$149M |
| 3 |
Twin Tree Management
Dallas,
Texas
|
-$66.8M |
| 4 |
Millennium Management
New York
|
-$65.6M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$57.8M |
